Skip to content
Visnia
CtrlK
EconomyAI buildoutMarket MapFundsWatchlist
Log in
Market cap
Revenue
Net income
Cash on hand
Gross margin
Net margin
EPS
P/E ratio
Search
Market mapFundsWatchlist
Visnia

RArcus Biosciences, Inc.

EconomyAI buildoutMarket MapFundsWatchlist
Log in
R

Arcus Biosciences, Inc.

  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Similar companies
  • News
  • Insider Transactions

News

News

  • Arcus Biosciences to Host Investor Event Featuring New Data for Casdatifan as a Treatment for Kidney Cancer Across Multiple Lines of Therapy
    Sep 22, 2026Arcus Biosciences Press Releases
  • Arcus Biosciences to Participate in Three Upcoming Investor Conferences
    Aug 26, 2026Arcus Biosciences Press Releases
  • Arcus Biosciences Reports Second-Quarter 2026 Financial Results and Provides a Pipeline Update
    Aug 5, 2026Arcus Biosciences Press Releases
  • Arcus Biosciences Announces Clinical Supply Agreement with AVEO Oncology to Evaluate Casdatifan in Combination with Tivozanib for Advanced Kidney Cancer Patients
    Jul 22, 2026Arcus Biosciences Press Releases
  • Arcus Biosciences and Summit Therapeutics Enter Into Clinical Trial Collaboration to Evaluate Casdatifan Combined with Ivonescimab in Kidney Cancer
    Jul 22, 2026Arcus Biosciences Press Releases
  • Arcus Biosciences to Host Conference Call to Discuss Second-Quarter 2026 Financial Results and Pipeline Updates
    Jul 21, 2026Arcus Biosciences Press Releases
  • New Research Published in Nature Links Clinical Activity with HIF‑2a Biology in Advanced Kidney Cancer Patients Treated with Casdatifan
    Jul 1, 2026Arcus Biosciences Press Releases
  • From Target to Translation: Revealing the Mechanism Behind HIF-2α Inhibition in Kidney Cancer
    Jul 1, 2026Arcus Biosciences

    A look at how ARC-20 connected tumor biology, blood-based biomarkers and clinical outcomes for casdatifan in kidney cancer.

  • Arcus Biosciences Announces Clinical Trial Collaboration and Supply Agreement to Evaluate Casdatifan in Combination with PD‑L1/VEGF‑A Bispecific Immunomodulator to Treat Kidney Cancer
    Jun 3, 2026Arcus Biosciences Press Releases
  • Arcus Biosciences to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
    May 26, 2026Arcus Biosciences Press Releases
  • Overview
  • Financial statements
  • Metrics
  • Quarterly earnings
  • Burn Rate
  • Similar companies
  • News
  • Insider Transactions
$26.87Close · Sep 22, 2026